business

Leerink Upholds Outperform Rating for Crinetics Pharmaceuticals (CRNX)

Yahoo Finance · Jun 17, 2026, 3:55 PM · Also reported by 3 other sources

Read full story on Yahoo Finance → More top stories

Also covered by

Investing.com Cytokinetics stock rating reaffirmed at Outperform by RBC Capital Investing.com Leerink reiterates Edgewise Therapeutics stock rating on trial data Investing.com Leerink reiterates Hims & Hers stock rating ahead of peptide meeting

Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop

Leerink Upholds Outperform Rating for Crinetics Pharmaceuticals (CRNX)

Also covered by

More in business